Faculty Collaboration Database

Medical College of Wisconsin

CTSI Research Informatics REDCap

Parameswaran Hari MD

Adjunct Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Member of the Cardiovascular Research Center

Send Message

Request Meeting

View Curriculum Vitae

Publications (391)

Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study. (Hari P, Latremouille-Viau D, Lin P, Guerin A, Sasane M) Medicine (Baltimore) 2024 Jun 28;103(26):e38609 PMID: 38941411 PMCID: PMC11466089 SCOPUS ID: 2-s2.0-85197197896 06/28/2024

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. (Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T) J Clin Oncol 2024 Aug 10;42(23):2757-2768 PMID: 38701390 PMCID: PMC11634105 SCOPUS ID: 2-s2.0-85201029574 05/03/2024 14 Citations

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. (Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM) Blood Cancer J 2024 Apr 22;14(1):69 PMID: 38649340 PMCID: PMC11035596 SCOPUS ID: 2-s2.0-85191093548 04/23/2024 23 Citations

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. (Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C) Blood Cancer J 2024 Mar 06;14(1):38 PMID: 38443358 PMCID: PMC10915134 SCOPUS ID: 2-s2.0-85186929795 03/06/2024 6 Citations

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. (Malek E, Kort J, Metheny L, Fu P, Li G, Hari P, Efebera Y, Callander NS, Qazilbash MH, Giralt S, Krishnan A, Stadtmauer EA, Lazarus HM) Transplant Cell Ther 2024 Jul;30(7):698.e1-698.e10 PMID: 38244697 PMCID: PMC12175559 SCOPUS ID: 2-s2.0-85194181757 01/21/2024 4 Citations

Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B) Br J Haematol 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023 6 Citations

Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance. (Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J) Leukemia 2024 Feb;38(2):383-385 PMID: 37919604 PMCID: PMC11326531 SCOPUS ID: 2-s2.0-85175540732 11/03/2023 1 Citation

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. (Malek E, Kort J, Metheny L, Fu P, Hari P, Li G, Efebera Y, Callander N, Qazilbash M, Giralt S, Krishnan A, Stadtmauer E, Lazarus H) Res Sq 2023 Sep 21 PMID: 37790413 PMCID: PMC10543370 10/04/2023

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) Lancet Haematol 2023 Nov;10(11):e890-e901 PMID: 37776872 PMCID: PMC10836587 SCOPUS ID: 2-s2.0-85173823660 10/01/2023 132 Citations

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant. (Ariza-Heredia EJ, Winston DJ, Rowley SD, Mullane K, Chandrasekar P, Hari P, Avery RK, Peggs KS, Kumar D, Nath R, Ljungman P, Mossad SB, El Haddad L, Shah DP, Jiang Y, Khawaja F, Dadwal S, Blanchard T, Chemaly RF) Open Forum Infect Dis 2023 Aug;10(8):ofad386 PMID: 37636519 PMCID: PMC10460252 SCOPUS ID: 2-s2.0-85171183062 08/28/2023 12 Citations

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen. (Palmen B, Hari P, D'Souza A, Abid MB) Haematologica 2023 Nov 01;108(11):3186-3190 PMID: 37051742 PMCID: PMC10620554 SCOPUS ID: 2-s2.0-85164779983 04/14/2023 14 Citations

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. (Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K) Blood Adv 2023 Sep 26;7(18):5549-5553 PMID: 36724511 PMCID: PMC10514068 SCOPUS ID: 2-s2.0-85164933174 02/02/2023 2 Citations

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. (Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M) Haematologica 2023 Aug 01;108(8):2249-2254 PMID: 36601982 PMCID: PMC10388259 SCOPUS ID: 2-s2.0-85166385557 01/06/2023 5 Citations

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. (Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A) J Immunother Cancer 2022 Dec;10(12) PMID: 36600653 PMCID: PMC9748991 SCOPUS ID: 2-s2.0-85145542316 01/06/2023 254 Citations

Exercise "CALM" and make CAR-T therapy work better. (Mei H, Hari P, Hu Y) Sci Bull (Beijing) 2022 Oct 15;67(19):1925-1928 PMID: 36546195 SCOPUS ID: 2-s2.0-85138068615 12/23/2022 4 Citations

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. (Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S) Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):68-77 PMID: 36357295 SCOPUS ID: 2-s2.0-85143521070 11/11/2022 13 Citations

Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. (Hodge A, Sheean P, O'Connor P, Tyler K, Kerschner A, Williams A, Jensik K, Visotcky A, D'Souza A, Hari P, Dhakal B, Chhabra S, Flynn KE, Hagen P, Stolley M) Support Care Cancer 2022 Dec;30(12):9771-9779 PMID: 36287278 SCOPUS ID: 2-s2.0-85140591976 10/27/2022 5 Citations

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. (Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schecter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath S) Lancet Haematol 2022 Dec;9(12):e897-e905 PMID: 36215989 SCOPUS ID: 2-s2.0-85142795300 10/11/2022 36 Citations

Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplant Cell Ther 2022 Oct;28(10):717 PMID: 36202527 SCOPUS ID: 2-s2.0-85101258094 10/07/2022

Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. (D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM) Transplant Cell Ther 2022 Oct;28(10):715-716 PMID: 36202526 SCOPUS ID: 2-s2.0-85108559179 10/07/2022 2 Citations

Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885, (S1083879120304146), (10.1016/j.bbmt.2020.07.005)] (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplantation and Cellular Therapy October 2022;28(10):717 SCOPUS ID: 2-s2.0-85101258094 10/01/2022

Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182, (S1083879120302251), (10.1016/j.bbmt.2020.04.013)] (D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM) Transplantation and Cellular Therapy October 2022;28(10):715-716 SCOPUS ID: 2-s2.0-85108559179 10/01/2022 2 Citations

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256 PMID: 36106394 PMCID: PMC9827178 SCOPUS ID: 2-s2.0-85145424654 09/16/2022 10 Citations

Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. (Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN) Am J Hematol 2022 Dec;97(12):1580-1588 PMID: 36068950 SCOPUS ID: 2-s2.0-85138335080 09/08/2022 23 Citations

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. (Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P) Transplant Cell Ther 2023 Jun;29(6):358.e1-358.e7 PMID: 35840087 PMCID: PMC10442072 SCOPUS ID: 2-s2.0-85151326035 07/16/2022 6 Citations

Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. (Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos MV, Moreau P, Usmani SZ, Olyslager Y, Schecter JM, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo IA, Lin Y, Diels J, Valluri S, Weisel K) Curr Med Res Opin 2022 Oct;38(10):1759-1767 PMID: 35815818 SCOPUS ID: 2-s2.0-85135867606 07/12/2022 5 Citations

FOXM1 regulates glycolysis and energy production in multiple myeloma. (Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S) Oncogene 2022 Aug;41(32):3899-3911 PMID: 35794249 PMCID: PMC9355869 SCOPUS ID: 2-s2.0-85133568311 07/07/2022 43 Citations

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. (Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, Chhabra S, Medvedova E, Godby KN, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS, Costa LJ) Am J Hematol 2022 Sep;97(9):1170-1177 PMID: 35731911 SCOPUS ID: 2-s2.0-85133435905 06/23/2022 7 Citations

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. (Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S) J Clin Oncol 2023 Feb 20;41(6):1265-1274 PMID: 35658469 PMCID: PMC9937098 SCOPUS ID: 2-s2.0-85134581882 06/07/2022 541 Citations

Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms. (Ponce SB, Chhabra S, Hari P, Firat S) Adv Radiat Oncol 2022;7(5):100964 PMID: 35647411 PMCID: PMC9130078 SCOPUS ID: 2-s2.0-85134477854 06/02/2022 10 Citations

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. (Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J) Blood Cancer J 2022 May 25;12(5):82 PMID: 35614050 PMCID: PMC9132975 SCOPUS ID: 2-s2.0-85130720530 05/26/2022 9 Citations

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. (Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, Sauber G, Yim S, Johnson B, Hari P, Schneider D, Dropulic B, Cusatis RN, Cole SW, Hillard CJ, Shah NN) Commun Med (Lond) 2022;2(1):49 PMID: 35603278 PMCID: PMC9098435 SCOPUS ID: 2-s2.0-85134214336 05/24/2022 14 Citations

Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. (Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN) Cytotherapy 2022 Aug;24(8):767-773 PMID: 35597752 SCOPUS ID: 2-s2.0-85130432792 05/22/2022 13 Citations

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. (D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE) Am J Hematol 2023 Jan;98(1):140-147 PMID: 35567778 PMCID: PMC9659666 SCOPUS ID: 2-s2.0-85130262056 05/15/2022 21 Citations

Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. (Shah N, Mojebi A, Ayers D, Cope S, Dhanasiri S, Davies FE, Hari P, Patel P, Hege K, Dhanda D) J Comp Eff Res 2022 Jul;11(10):737-749 PMID: 35485211 SCOPUS ID: 2-s2.0-85132454814 04/30/2022 15 Citations

Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. (Schroeder MA, Hari PN, Blithe A, Paranagama D, Bhatt V, DiPersio JF) Bone Marrow Transplant 2022 Jun;57(6):975-981 PMID: 35437311 SCOPUS ID: 2-s2.0-85128266304 04/20/2022 12 Citations

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. (Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM) Yale J Biol Med 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022 5 Citations

Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. (Nathwani N, Bell J, Cherepanov D, Sowell FG, Shah R, McCarrier K, Hari P) Support Care Cancer 2022 Jul;30(7):5859-5869 PMID: 35364733 PMCID: PMC9135799 SCOPUS ID: 2-s2.0-85127563469 04/03/2022 16 Citations

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. (Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN) JAMA Oncol 2022 May 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022 31 Citations

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. (Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P) Blood Cancer J 2022 Feb 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 02/26/2022 40 Citations

A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis. (Hari P, Chhabra S) Transplant Cell Ther 2022 May;28(5):242-247 PMID: 35196581 SCOPUS ID: 2-s2.0-85126904084 02/24/2022 3 Citations

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. (Dhakal B, Sharma S, Balcioglu M, Shchegrova S, Malhotra M, Zimmermann B, Billings PR, Harrington A, Sethi H, Aleshin A, Hari PN) Front Oncol 2022;12:786451 PMID: 35186734 PMCID: PMC8848740 SCOPUS ID: 2-s2.0-85124893548 02/22/2022 20 Citations

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. (Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS) Clin Lymphoma Myeloma Leuk 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022 3 Citations

Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). (Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D) Blood Cancer J 2022 Feb 10;12(2):27 PMID: 35145071 PMCID: PMC8831597 SCOPUS ID: 2-s2.0-85124447448 02/12/2022 36 Citations

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, McCarthy PL, Munshi NC) Lancet Haematol 2022 Feb;9(2):e143-e161 PMID: 35114152 SCOPUS ID: 2-s2.0-85123758879 02/04/2022 156 Citations

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. (Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P) Blood Adv 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021 55 Citations

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) J Clin Oncol 2022 Sep 01;40(25):2901-2912 PMID: 34898239 SCOPUS ID: 2-s2.0-85137134934 12/14/2021 208 Citations

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. (Merz M, Goldschmidt H, Hari P, Agha M, Diels J, Ghilotti F, Perualila NJ, Cabrieto J, Haefliger B, Sliwka H, Schecter JM, Jackson CC, Olyslager Y, Akram M, Nesheiwat T, Kellermann L, Jagannath S) Cancers (Basel) 2021 Nov 29;13(23) PMID: 34885106 PMCID: PMC8656798 SCOPUS ID: 2-s2.0-85120078718 12/11/2021 13 Citations

WDR26 and MTF2 are therapeutic targets in multiple myeloma. (Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S) J Hematol Oncol 2021 Dec 07;14(1):203 PMID: 34876184 PMCID: PMC8650373 SCOPUS ID: 2-s2.0-85120899924 12/09/2021 8 Citations

Adjusted comparison of outcomes between patients from cartitude-1 versus multiple myeloma patients with prior exposure to pi, imid and anti-cd-38 from a german registry (Merz M, Goldschmidt H, Hari P, Agha M, Diels J, Ghilotti F, Perualila NJ, Cabrieto J, Haefliger B, Sliwka H, Schecter JM, Jackson CC, Olyslager Y, Akram M, Nesheiwat T, Kellermann L, Jagannath S) Cancers December-1 2021;13(23) SCOPUS ID: 2-s2.0-85120078718 12/01/2021 13 Citations

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. (Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schecter JM, Kumar S, Hari P) Clin Lymphoma Myeloma Leuk 2022 May;22(5):326-335 PMID: 34840088 SCOPUS ID: 2-s2.0-85120376442 11/30/2021 41 Citations

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. (Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, Kumar S, Costa LJ) Leukemia 2022 Mar;36(3):877-880 PMID: 34802043 SCOPUS ID: 2-s2.0-85119448679 11/22/2021 34 Citations

Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? (Palen K, Zurko J, Johnson BD, Hari P, Shah NN) Cytotherapy 2021 Nov;23(11):985-990 PMID: 34538575 SCOPUS ID: 2-s2.0-85115015094 09/21/2021 17 Citations

Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. (Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM) Transplant Cell Ther 2021 Nov;27(11):885-907 PMID: 34461278 PMCID: PMC8556300 SCOPUS ID: 2-s2.0-85116810681 08/31/2021 18 Citations

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. (Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B) Cells 2021 Aug 02;10(8) PMID: 34440730 PMCID: PMC8391934 SCOPUS ID: 2-s2.0-85115041797 08/28/2021 28 Citations

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. (Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A) Cancer 2021 Nov 15;127(22):4233-4239 PMID: 34374445 PMCID: PMC8699178 SCOPUS ID: 2-s2.0-85112102705 08/11/2021 16 Citations

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. (Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M) Blood 2021 Oct 07;138(14):1278-1281 PMID: 34339501 PMCID: PMC8332674 SCOPUS ID: 2-s2.0-85114112109 08/03/2021 107 Citations

Management Strategies for Dealing With Surges of the COVID-19 Pandemic. (Raveendran AV, Kesavadev J, Hari P, Krishnan G) Cureus 2021 Jun;13(6):e15794 PMID: 34295599 PMCID: PMC8293859 07/24/2021

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Oct;21(10):e775-e781 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021 5 Citations

Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. (Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A) Leuk Res 2021 Oct;109:106648 PMID: 34182226 SCOPUS ID: 2-s2.0-85109506946 06/29/2021

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. (Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S) Lancet 2021 Jul 24;398(10297):314-324 PMID: 34175021 SCOPUS ID: 2-s2.0-85111003312 06/28/2021 1396 Citations

Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. (Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S) Front Immunol 2021;12:667054 PMID: 34149703 PMCID: PMC8206561 SCOPUS ID: 2-s2.0-85108140164 06/22/2021 6 Citations

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A) Leukemia 2021 Jul;35(7):2141 PMID: 34091601 SCOPUS ID: 2-s2.0-85107532822 06/07/2021 1 Citation

SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopenia. (Zhu W, Zheng Y, Yu M, Wei J, Zhang Y, Topchyan P, Nguyen C, Janecke R, Kreuziger LB, White GC, Hari P, Aster R, Cui W, Jobe S, Graham MB, Wang D, Wen R) Res Sq 2021 Apr 26 PMID: 34013243 PMCID: PMC8132233 05/21/2021

Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. (Mohan M, Hari P, Dhakal B) JCO Oncol Pract 2021 Jul;17(7):405-413 PMID: 34003675 SCOPUS ID: 2-s2.0-85111055909 05/19/2021 19 Citations

KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. (Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF) Clin Lymphoma Myeloma Leuk 2021 Aug;21(8):526-535 PMID: 33985931 SCOPUS ID: 2-s2.0-85105544057 05/15/2021 21 Citations

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. (Biran N, Dhakal B, Lentzsch S, Siegel D, Usmani SZ, Rossi A, Rosenbaum C, Bhutani D, Vesole DH, Rodriguez C, Nooka AK, van Rhee F, Stork-Sloots L, de Snoo F, Bhattacharyya PK, Dash DP, Zümrütçü S, van Vliet MH, Hari P, Niesvizky R) EJHaem 2021 Aug;2(3):375-384 PMID: 35844693 PMCID: PMC9175784 05/11/2021

Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation. (Thapa B, Ahmed G, Mohan M, Shponka V, Hari P) Case Rep Hematol 2021;2021:5590975 PMID: 33884207 PMCID: PMC8041536 04/23/2021

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. (Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN) Haematologica 2021 Oct 01;106(10):2788-2790 PMID: 33853295 PMCID: PMC8485669 SCOPUS ID: 2-s2.0-85116219490 04/16/2021 5 Citations

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A) Leukemia 2021 Jun;35(6):1828 PMID: 33782538 PMCID: PMC8188513 SCOPUS ID: 2-s2.0-85103400893 03/31/2021

Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. (Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A) Transplant Cell Ther 2021 Mar;27(3):264.e1-264.e7 PMID: 33781533 PMCID: PMC8010222 SCOPUS ID: 2-s2.0-85101183550 03/31/2021 15 Citations

Plegia to walking: AHSCBMT in severe NMOSD relapse. (Carlisle N, Hari P, Brod S) BMJ Neurol Open 2020;2(2):e000073 PMID: 33681798 PMCID: PMC7903183 SCOPUS ID: 2-s2.0-85105891279 03/09/2021 4 Citations

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG) Lancet Oncol 2021 Mar;22(3):e105-e118 PMID: 33662288 SCOPUS ID: 2-s2.0-85101689680 03/05/2021 248 Citations

Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden (Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A) Transplantation and Cellular Therapy March 2021;27(3):264-264.e7 SCOPUS ID: 2-s2.0-85101183550 03/01/2021 15 Citations

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG) Lancet Oncology March 2021;22(3):e105-e118 SCOPUS ID: 2-s2.0-85101689680 03/01/2021 248 Citations

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma (Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T) Leukemia December 2020;34(12):3298-3309 SCOPUS ID: 2-s2.0-85084684633 12/01/2020 46 Citations

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma (Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D’Souza A) Cancer 1 December 2020;126(23):5077-5087 SCOPUS ID: 2-s2.0-85091306660 12/01/2020 64 Citations

In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". (Reddy P, Davies S, Majhail N, Sandmaier B, Hari P, Cutler C) Blood Adv 2020 Nov 10;4(21):5431-5432 PMID: 33152057 PMCID: PMC7656930 SCOPUS ID: 2-s2.0-85096913166 11/06/2020 1 Citation

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. (Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P) Br J Haematol 2020 Nov;191(3):442-452 PMID: 33094839 PMCID: PMC7990054 SCOPUS ID: 2-s2.0-85088463591 10/24/2020 11 Citations

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020 399 Citations

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. (Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L) Am J Hematol 2021 Jan;96(1):E5-E8 PMID: 32974944 SCOPUS ID: 2-s2.0-85092920395 09/26/2020 28 Citations

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. (Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A) Cancer 2021 Jan 01;127(1):82-92 PMID: 32966625 PMCID: PMC7736245 SCOPUS ID: 2-s2.0-85091313309 09/24/2020 23 Citations

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. (Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A) Cancer 2020 Dec 01;126(23):5077-5087 PMID: 32965680 PMCID: PMC8063213 SCOPUS ID: 2-s2.0-85091306660 09/24/2020 64 Citations

Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2020 Dec;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020 5 Citations

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. (Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ) Leuk Lymphoma 2020 Dec;61(14):3484-3492 PMID: 32865474 PMCID: PMC7786301 SCOPUS ID: 2-s2.0-85089967898 09/01/2020 6 Citations

Autonomic nervous system control of multiple myeloma. (Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S) Blood Rev 2021 Mar;46:100741 PMID: 32807576 PMCID: PMC7876165 SCOPUS ID: 2-s2.0-85089534779 08/19/2020 20 Citations

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. (Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B) Leukemia 2021 Jan;35(1):18-30 PMID: 32778736 SCOPUS ID: 2-s2.0-85089253567 08/12/2020 103 Citations

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets. (Oldham RAA, Faber ML, Keppel TR, Buchberger AR, Waas M, Hari P, Gundry RL, Medin JA) J Immunother Cancer 2020 Aug;8(2) PMID: 32771993 PMCID: PMC7418848 SCOPUS ID: 2-s2.0-85089262124 08/11/2020 16 Citations

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. (Dhakal B, Hari PN, Usmani SZ, Hamadani M) Bone Marrow Transplant 2021 Jan;56(1):9-19 PMID: 32770147 SCOPUS ID: 2-s2.0-85089253834 08/10/2020 26 Citations

Salvage second transplantation in relapsed multiple myeloma. (Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P) Leukemia 2021 Apr;35(4):1214-1217 PMID: 32747684 PMCID: PMC8020391 SCOPUS ID: 2-s2.0-85088870056 08/05/2020 24 Citations

Trends in the use of therapeutic plasma exchange in multiple myeloma (Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P) Journal of Clinical Apheresis 1 August 2020;35(4):307-315 SCOPUS ID: 2-s2.0-85086092696 08/01/2020 8 Citations

Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. (Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A) Bone Marrow Transplant 2021 Jan;56(1):225-231 PMID: 32732941 PMCID: PMC7855279 SCOPUS ID: 2-s2.0-85088830942 08/01/2020 45 Citations

Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. (Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020 20 Citations

Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020 7 Citations

Primary refractory multiple myeloma: a real-world experience with 85 cases. (Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK) Leuk Lymphoma 2020 Dec;61(12):2868-2875 PMID: 32623944 SCOPUS ID: 2-s2.0-85087612188 07/07/2020 12 Citations

Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression (Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M) British Journal of Haematology 1 July 2020;190(2):e98-e101 SCOPUS ID: 2-s2.0-85084830591 07/01/2020 11 Citations

Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. (Shah NN, Jerkins JH, Johnson BD, Hari P) JCO Oncol Pract 2020 Sep;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020 2 Citations

Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". (Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, Shaw BE) Biol Blood Marrow Transplant 2020 Sep;26(9):e241-e242 PMID: 32589922 PMCID: PMC7309826 SCOPUS ID: 2-s2.0-85087728830 06/27/2020 1 Citation

Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. (Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S) Biol Blood Marrow Transplant 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020 20 Citations

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. (D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN) EClinicalMedicine 2020 Jun;23:100361 PMID: 32529175 PMCID: PMC7280748 SCOPUS ID: 2-s2.0-85085967990 06/13/2020 32 Citations

Trends in the use of therapeutic plasma exchange in multiple myeloma. (Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P) J Clin Apher 2020 Aug;35(4):307-315 PMID: 32516865 SCOPUS ID: 2-s2.0-85086092696 06/10/2020 8 Citations

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. (Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM) Haematologica 2021 Jun 01;106(6):1599-1607 PMID: 32499241 PMCID: PMC8168504 SCOPUS ID: 2-s2.0-85107390434 06/06/2020 34 Citations

Multiple myeloma and COVID-19. (Dhakal B, D'Souza A, Chhabra S, Hari P) Leukemia 2020 Jul;34(7):1961-1963 PMID: 32475990 SCOPUS ID: 2-s2.0-85085898339 06/02/2020 29 Citations

Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation (Nikolaenko L, Chhabra S, Biran N, Chowdhury A, Hari PN, Krishnan A, Richter J) Clinical Lymphoma Myeloma and Leukemia June 2020;20(6):407-414 SCOPUS ID: 2-s2.0-85082806128 06/01/2020 13 Citations

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial (D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN) Eclinicalmedicine June 2020;23 SCOPUS ID: 2-s2.0-85085967990 06/01/2020 32 Citations

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. (D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM) Biol Blood Marrow Transplant 2020 Aug;26(8):e177-e182 PMID: 32438042 PMCID: PMC7404814 SCOPUS ID: 2-s2.0-85085969206 05/22/2020 466 Citations

Biomarkers in individualized management of chimeric antigen receptor T cell therapy. (Du M, Hari P, Hu Y, Mei H) Biomark Res 2020;8:13 PMID: 32426136 PMCID: PMC7216329 SCOPUS ID: 2-s2.0-85085127228 05/20/2020 30 Citations

Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. (Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M) Br J Haematol 2020 Jul;190(2):e98-e101 PMID: 32415780 SCOPUS ID: 2-s2.0-85084830591 05/18/2020 11 Citations

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. (Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T) Leukemia 2020 Dec;34(12):3298-3309 PMID: 32409691 PMCID: PMC7685976 SCOPUS ID: 2-s2.0-85084684633 05/16/2020 44 Citations

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. (Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P) Blood Adv 2020 May 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020 56 Citations

Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. (Bhasin B, Szabo A, Wu R, Saad ER, Hari P, Dhakal B, Chhabra S, D'Souza A) Clin Lymphoma Myeloma Leuk 2020 Aug;20(8):e468-e473 PMID: 32340914 PMCID: PMC7450520 SCOPUS ID: 2-s2.0-85083660475 04/29/2020 4 Citations

Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A) Leukemia 2020 Dec;34(12):3338-3347 PMID: 32313109 PMCID: PMC7572530 SCOPUS ID: 2-s2.0-85083712292 04/22/2020 43 Citations

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. (Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Mazur P, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Długosz-Danecka M, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Vesole DH) Leuk Lymphoma 2020 Aug;61(8):1885-1893 PMID: 32306794 SCOPUS ID: 2-s2.0-85083656922 04/21/2020 6 Citations

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. (Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer EA, Rosinol L, Krishnan AY, Gahrton G, Bruno B) Bone Marrow Transplant 2020 Sep;55(9):1810-1816 PMID: 32286506 PMCID: PMC7483973 SCOPUS ID: 2-s2.0-85083806858 04/15/2020 41 Citations

Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. (Nikolaenko L, Chhabra S, Biran N, Chowdhury A, Hari PN, Krishnan A, Richter J) Clin Lymphoma Myeloma Leuk 2020 Jun;20(6):407-414 PMID: 32249196 PMCID: PMC9009296 SCOPUS ID: 2-s2.0-85082806128 04/07/2020 13 Citations

Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. (Richardson PG, Nagler A, Ben-Yehuda D, Badros A, Hari PN, Hajek R, Spicka I, Kaya H, LeBlanc R, Yoon SS, Kim K, Martinez-Lopez J, Mittelman M, Shpilberg O, Blake P, Hideshima T, Colson K, Laubach JP, Ghobrial IM, Leiba M, Gatt ME, Sportelli P, Chen M, Anderson KC) EJHaem 2020 Jul;1(1):94-102 PMID: 35847734 PMCID: PMC9175725 04/06/2020

Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN) Cancer 2020 Jun 15;126(12):2791-2801 PMID: 32154922 SCOPUS ID: 2-s2.0-85081273628 03/11/2020 5 Citations

Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2-s2.0-85083636589 03/07/2020 15 Citations

Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. (Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, Avery RK, Hari P, Peggs KS, Kumar D, Nath R, Ljungman P, Mossad SB, Dadwal SS, Blanchard T, Shah DP, Jiang Y, Ariza-Heredia E) Clin Infect Dis 2020 Dec 03;71(9):2365-2374 PMID: 32076709 PMCID: PMC7713694 SCOPUS ID: 2-s2.0-85093869370 02/23/2020 98 Citations

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. (Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Davila Valls J, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Długosz-Danecka M, Grosicki S, Vesole DH) Am J Hematol 2020 May;95(5):503-509 PMID: 32072687 SCOPUS ID: 2-s2.0-85081026797 02/20/2020 28 Citations

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW) Blood Adv 2020 Feb 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020 48 Citations

Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020 18 Citations

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD) Lancet Oncol 2020 Feb;21(2):207-221 PMID: 31859245 SCOPUS ID: 2-s2.0-85078479667 12/21/2019 697 Citations

Gut microbiome and CAR-T therapy. (Abid MB, Shah NN, Maatman TC, Hari PN) Exp Hematol Oncol 2019;8:31 PMID: 31827982 PMCID: PMC6862813 SCOPUS ID: 2-s2.0-85075584597 12/13/2019 44 Citations

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. (Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M) Leuk Lymphoma 2020 Apr;61(4):869-874 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019 24 Citations

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. (Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E) Biol Blood Marrow Transplant 2020 Apr;26(4):798-804 PMID: 31756536 PMCID: PMC7198329 SCOPUS ID: 2-s2.0-85077165933 11/23/2019 34 Citations

Gut microbiome and CAR-T therapy (Abid MB, Shah NN, Maatman TC, Hari PN) Experimental Hematology and Oncology 19 November 2019;8(1) SCOPUS ID: 2-s2.0-85075584597 11/19/2019 44 Citations

Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs. (Hari P, Ung B, Abouzaid S, Agarwal A, Parikh K) Future Oncol 2019 Dec;15(35):4045-4056 PMID: 31625415 SCOPUS ID: 2-s2.0-85075795524 10/19/2019 7 Citations

An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. (Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A) J Clin Apher 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019 3 Citations

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. (Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL) Biol Blood Marrow Transplant 2020 Jan;26(1):e7-e15 PMID: 31526843 PMCID: PMC6942175 SCOPUS ID: 2-s2.0-85073734108 09/19/2019 16 Citations

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. (Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, McSweeney PA, Storb R, Sorror ML) Bone Marrow Transplant 2020 Jan;55(1):172-181 PMID: 31481800 PMCID: PMC6940535 SCOPUS ID: 2-s2.0-85072196038 09/05/2019 11 Citations

Oprozomib in patients with newly diagnosed multiple myeloma (Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P) Blood Cancer Journal 1 September 2019;9(9) SCOPUS ID: 2-s2.0-85071028408 09/01/2019 22 Citations

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. (Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D) Hematol Oncol Stem Cell Ther 2020 Mar;13(1):7-16 PMID: 31449781 SCOPUS ID: 2-s2.0-85080069497 08/27/2019 22 Citations

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. (Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J) Hematol Oncol Stem Cell Ther 2020 Sep;13(3):131-142 PMID: 31449780 PMCID: PMC7125509 SCOPUS ID: 2-s2.0-85071270497 08/27/2019 18 Citations

Oprozomib in patients with newly diagnosed multiple myeloma. (Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P) Blood Cancer J 2019 Aug 16;9(9):66 PMID: 31420532 PMCID: PMC6697695 SCOPUS ID: 2-s2.0-85071028408 08/20/2019 22 Citations

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 Jul 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019 20 Citations

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019 3 Citations

Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. (D'Souza A, Hari P, Pasquini M, Jacobsen K, Flynn KE) Amyloid 2019;26(sup1):87-88 PMID: 31343353 PMCID: PMC7108667 SCOPUS ID: 2-s2.0-85069630470 07/26/2019 2 Citations

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. (Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S, KEYNOTE-183 Investigators) Lancet Haematol 2019 Sep;6(9):e459-e469 PMID: 31327687 SCOPUS ID: 2-s2.0-85071223893 07/23/2019 230 Citations

Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. (Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT) Transpl Infect Dis 2019 Oct;21(5):e13145 PMID: 31301099 PMCID: PMC7239317 SCOPUS ID: 2-s2.0-85073491232 07/14/2019 24 Citations

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M) JAMA Netw Open 2019 Jul 03;2(7):e196476 PMID: 31276175 PMCID: PMC12124690 SCOPUS ID: 2-s2.0-85068511187 07/06/2019 17 Citations

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. (Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH) Leuk Res 2019 Aug;83:106172 PMID: 31229804 PMCID: PMC6871647 SCOPUS ID: 2-s2.0-85067430808 06/24/2019 18 Citations

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. (Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S) Haematologica 2020 Mar;105(3):e111-e115 PMID: 31221780 PMCID: PMC7049347 SCOPUS ID: 2-s2.0-85080963194 06/22/2019 5 Citations

Germline Risk Contribution to Genomic Instability in Multiple Myeloma. (Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P) Front Genet 2019;10:424 PMID: 31139207 PMCID: PMC6518313 SCOPUS ID: 2-s2.0-85067859695 05/30/2019 21 Citations

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. (Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J) Biol Blood Marrow Transplant 2019 Dec;25(12):2322-2329 PMID: 31071457 SCOPUS ID: 2-s2.0-85066242026 05/10/2019 21 Citations

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. (Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D) Biol Blood Marrow Transplant 2019 Dec;25(12):2330-2337 PMID: 31002990 SCOPUS ID: 2-s2.0-85065760511 04/20/2019 21 Citations

When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. (Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A) Clin Lymphoma Myeloma Leuk 2019 Jun;19(6):e251-e258 PMID: 30987953 SCOPUS ID: 2-s2.0-85064179757 04/17/2019 9 Citations

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019 82 Citations

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 Aug;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019 25 Citations

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. (Shah NN, Maatman T, Hari P, Johnson B) Front Oncol 2019;9:146 PMID: 30915277 PMCID: PMC6423158 SCOPUS ID: 2-s2.0-85063343499 03/28/2019 153 Citations

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. (Patel G, Hari P, Szabo A, Rein L, Kreuziger LB, Chhabra S, Dhakal B, D'Souza A) Hematol Oncol Stem Cell Ther 2019 Mar;12(1):10-14 PMID: 30879471 SCOPUS ID: 2-s2.0-85052754317 03/19/2019 29 Citations

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. (Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S) Biol Blood Marrow Transplant 2019 Jul;25(7):1456-1464 PMID: 30878605 SCOPUS ID: 2-s2.0-85064323899 03/18/2019 21 Citations

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. (Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ) Leukemia 2019 Sep;33(9):2266-2275 PMID: 30858549 PMCID: PMC6820050 SCOPUS ID: 2-s2.0-85062828886 03/13/2019 542 Citations

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. (Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F) Leuk Lymphoma 2019 Oct;60(10):2558-2562 PMID: 30845856 PMCID: PMC7176050 SCOPUS ID: 2-s2.0-85062788299 03/09/2019 16 Citations

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). (Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J) Lancet Haematol 2019 Mar;6(3):e132-e143 PMID: 30824040 PMCID: PMC6503965 SCOPUS ID: 2-s2.0-85061920512 03/03/2019 245 Citations

Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. (Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P) Biol Blood Marrow Transplant 2019 Jun;25(6):1099-1106 PMID: 30794931 PMCID: PMC6559839 SCOPUS ID: 2-s2.0-85064954131 02/23/2019 13 Citations

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG) Leukemia 2019 Jul;33(7):1736-1746 PMID: 30696949 PMCID: PMC6755968 SCOPUS ID: 2-s2.0-85060937214 01/31/2019 44 Citations

Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. (Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M) Bone Marrow Transplant 2019 Aug;54(8):1354-1360 PMID: 30696997 PMCID: PMC7001099 SCOPUS ID: 2-s2.0-85060913611 01/31/2019 21 Citations

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. (Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A) J Clin Oncol 2019 Mar 01;37(7):589-597 PMID: 30653422 PMCID: PMC6553842 SCOPUS ID: 2-s2.0-85064136756 01/18/2019 235 Citations

Hematopoietic cell transplantation for light-chain amyloidosis (D’Souza A, Hari P) Hematopoietic Cell Transplantation for Malignant Conditions 1 January 2019:255-261 SCOPUS ID: 2-s2.0-85082284017 01/01/2019

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. (Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P) Biol Blood Marrow Transplant 2019 Apr;25(4):683-688 PMID: 30579965 PMCID: PMC6453717 SCOPUS ID: 2-s2.0-85060511135 12/24/2018 25 Citations

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018 31 Citations

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. (Vazirabad I, Chhabra S, Nytes J, Mehra V, Narra RK, Szabo A, Jerkins JH, Dhakal B, Hari P, Anderson MW) Biol Blood Marrow Transplant 2019 May;25(5):921-931 PMID: 30537549 SCOPUS ID: 2-s2.0-85060298203 12/12/2018 25 Citations

Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. (Hari P, Blazer M, Raju A, Farrelly E, Labotka R, Skacel T, Romanus D) Expert Rev Hematol 2019 Jan;12(1):71-79 PMID: 30513016 SCOPUS ID: 2-s2.0-85058444317 12/05/2018 4 Citations

Autologous hematopoietic cell transplantation (Lazarus HM, Hamadani M, Hari PN) Devita Hellman and Rosenberg S Cancer Principles Practice of Oncology 16 November 2018:2008-2019 SCOPUS ID: 2-s2.0-85061205146 11/16/2018

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. (Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL) Biol Blood Marrow Transplant 2019 Apr;25(4):699-711 PMID: 30423480 PMCID: PMC6453753 SCOPUS ID: 2-s2.0-85058455309 11/14/2018 17 Citations

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. (Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE) Haematologica 2019 Apr;104(4):844-854 PMID: 30381298 PMCID: PMC6442962 SCOPUS ID: 2-s2.0-85064008651 11/02/2018 18 Citations

Novel biomarkers in multiple myeloma. (Levin A, Hari P, Dhakal B) Transl Res 2018 Nov;201:49-59 PMID: 30301522 SCOPUS ID: 2-s2.0-85050195259 10/12/2018 36 Citations

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. (Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R) Haematologica 2019 Feb;104(2):380-391 PMID: 30262560 PMCID: PMC6355483 SCOPUS ID: 2-s2.0-85061057881 09/29/2018 28 Citations

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. (Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN) Biol Blood Marrow Transplant 2019 Jan;25(1):e33-e38 PMID: 30244105 SCOPUS ID: 2-s2.0-85055445894 09/24/2018 17 Citations

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. (Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P) Biol Blood Marrow Transplant 2019 Feb;25(2):335-342 PMID: 30243581 PMCID: PMC6339830 SCOPUS ID: 2-s2.0-85055703569 09/24/2018 23 Citations

Recent advances in understanding and treating immunoglobulin light chain amyloidosis. (Badar T, D'Souza A, Hari P) F1000Res 2018;7 PMID: 30228867 PMCID: PMC6117860 SCOPUS ID: 2-s2.0-85052967237 09/20/2018 16 Citations

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. (Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A) Biol Blood Marrow Transplant 2018 Dec;24(12):2443-2449 PMID: 30142419 PMCID: PMC6293469 SCOPUS ID: 2-s2.0-85054709914 08/25/2018 12 Citations

Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma-Reply. (Dhakal B, Szabo A, Hari P) JAMA Oncol 2018 Nov 01;4(11):1618 PMID: 30098154 SCOPUS ID: 2-s2.0-85052681406 08/12/2018 2 Citations

Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018 35 Citations

Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. (Wright NL, Flynn KE, Brazauskas R, Hari P, D'Souza A) Amyloid 2018 Jun;25(2):129-134 PMID: 30032653 SCOPUS ID: 2-s2.0-85050259150 07/24/2018 6 Citations

Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. (Costa LJ, Godby KN, Chhabra S, Cornell RF, Hari P, Bhatia S) Br J Haematol 2018 Aug;182(4):513-520 PMID: 29974936 SCOPUS ID: 2-s2.0-85050466984 07/06/2018 24 Citations

Final outcomes of escalated melphalan 280 mg/m² with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. (Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH) Bone Marrow Transplant 2019 Feb;54(2):293-299 PMID: 29907806 SCOPUS ID: 2-s2.0-85048569397 06/17/2018 12 Citations

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593 PMID: 29793446 PMCID: PMC5968588 SCOPUS ID: 2-s2.0-85047544800 05/26/2018 34 Citations

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 Aug;24(8):1610-1614 PMID: 29751116 SCOPUS ID: 2-s2.0-85048069667 05/12/2018 9 Citations

Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. (Hari P, Lin HM, Zhu Y, Berg D, Richardson PG, Moreau P) J Med Econ 2018 Aug;21(8):793-798 PMID: 29741409 SCOPUS ID: 2-s2.0-85047663698 05/10/2018 7 Citations

Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. (Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P, Padmanabhan A) Lancet Haematol 2018 May;5(5):e220-e231 PMID: 29703336 PMCID: PMC6437775 SCOPUS ID: 2-s2.0-85046022775 04/29/2018 103 Citations

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. (D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P) Contemp Clin Trials Commun 2017 Dec;8:33-38 PMID: 29696194 PMCID: PMC5898504 SCOPUS ID: 2-s2.0-85027981960 04/27/2018 17 Citations

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 Aug;24(8):1664-1670 PMID: 29680516 SCOPUS ID: 2-s2.0-85047194888 04/24/2018 42 Citations

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 Sep;53(9):1210-1213 PMID: 29679076 SCOPUS ID: 2-s2.0-85045751124 04/22/2018 7 Citations

Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. (Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG) Leukemia 2018 Sep;32(9):2032-2036 PMID: 29568098 PMCID: PMC6127091 SCOPUS ID: 2-s2.0-85044287939 03/24/2018 11 Citations

Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. (Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V) Biol Blood Marrow Transplant 2018 May;24(5):983-988 PMID: 29410340 SCOPUS ID: 2-s2.0-85042234569 02/08/2018 4 Citations

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. (Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA) Biol Blood Marrow Transplant 2018 Jul;24(7):1379-1385 PMID: 29410301 PMCID: PMC7590532 SCOPUS ID: 2-s2.0-85046706138 02/08/2018 19 Citations

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. (Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A) Clin Lymphoma Myeloma Leuk 2018 Feb;18(2):152-160 PMID: 29395837 SCOPUS ID: 2-s2.0-85041213283 02/06/2018 37 Citations

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 Apr;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018 44 Citations

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. (Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO) Biol Blood Marrow Transplant 2018 May;24(5):895-908 PMID: 29339270 PMCID: PMC7187910 SCOPUS ID: 2-s2.0-85041640816 01/18/2018 11 Citations

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350 PMID: 29302684 PMCID: PMC5885822 SCOPUS ID: 2-s2.0-85045789349 01/06/2018 143 Citations

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. (Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V) Amyloid 2018 Mar;25(1):1-7 PMID: 29303358 SCOPUS ID: 2-s2.0-85040978610 01/06/2018 16 Citations

Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults (Hamadani M, Hari PN) Hematology Basic Principles and Practice 2018:1596-1607 SCOPUS ID: 2-s2.0-85055854165 01/01/2018 1 Citation

Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. (Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA) Cytotherapy 2018 Mar;20(3):394-406 PMID: 29287970 SCOPUS ID: 2-s2.0-85039050230 12/31/2017 99 Citations

Chemo-Mobilization in Myeloma-Diminishing Returns in the Era of Novel Agent Induction? (Hari P) Biol Blood Marrow Transplant 2018 Feb;24(2):203-204 PMID: 29272697 SCOPUS ID: 2-s2.0-85038871080 12/23/2017 1 Citation

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. (Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A) Leukemia 2018 Apr;32(4):986-995 PMID: 29263438 PMCID: PMC5871538 SCOPUS ID: 2-s2.0-85044662461 12/22/2017 74 Citations

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. (Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P) Biol Blood Marrow Transplant 2018 Mar;24(3):478-485 PMID: 29079457 PMCID: PMC5826888 SCOPUS ID: 2-s2.0-85035213070 10/29/2017 38 Citations

The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. (Hari P, Romanus D, Luptakova K, Blazer M, Yong C, Raju A, Farrelly E, Labotka R, Morrison VA) J Geriatr Oncol 2018 Mar;9(2):138-144 PMID: 29056336 SCOPUS ID: 2-s2.0-85031819074 10/24/2017 33 Citations

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. (Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S) Br J Haematol 2017 Dec;179(5):781-789 PMID: 28980314 SCOPUS ID: 2-s2.0-85035114874 10/06/2017 78 Citations

Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. (Gajewski JL, McClellan MB, Majhail NS, Hari PN, Bredeson CN, Maziarz RT, LeMaistre CF, Lill MC, Farnia SH, Komanduri KV, Boo MJ) Biol Blood Marrow Transplant 2018 Jan;24(1):4-12 PMID: 28963077 SCOPUS ID: 2-s2.0-85033395802 10/01/2017 8 Citations

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. (Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A) Bone Marrow Transplant 2017 Dec;52(12):1616-1622 PMID: 28920949 PMCID: PMC5859934 SCOPUS ID: 2-s2.0-85041543565 09/19/2017 54 Citations

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. (Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A) Hematol Oncol Stem Cell Ther 2018 Jun;11(2):105-111 PMID: 28830801 PMCID: PMC12590447 SCOPUS ID: 2-s2.0-85027963716 08/24/2017 10 Citations

Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma. (Hari P, Romanus D, Henk HJ, Becker LK, Noga SJ, Morrison VA) J Clin Pharm Ther 2018 Feb;43(1):45-51 PMID: 28833305 SCOPUS ID: 2-s2.0-85040020104 08/24/2017 3 Citations

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. (Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL) Lancet Haematol 2017 Sep;4(9):e431-e442 PMID: 28826616 PMCID: PMC5718627 SCOPUS ID: 2-s2.0-85027488718 08/23/2017 155 Citations

Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Nov;23(11):1955-1960 PMID: 28757436 SCOPUS ID: 2-s2.0-85028446880 08/02/2017 29 Citations

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. (Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2017 Jul;17(7):408-414 PMID: 28756899 SCOPUS ID: 2-s2.0-85026407137 08/02/2017 9 Citations

Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 SCOPUS ID: 2-s2.0-85026445343 07/13/2017 7 Citations

Liver biopsy findings in patients with hematopoietic cell transplantation. (Eskandari F, Rowan DJ, Hari P, Kapke J, Schneidewend R, E Hagen C, Oshima K) Hum Pathol 2017 Aug;66:136-143 PMID: 28688898 SCOPUS ID: 2-s2.0-85026914113 07/10/2017 10 Citations

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. (D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P) Leukemia 2017 Sep;31(9):1998-2000 PMID: 28663578 PMCID: PMC5587375 SCOPUS ID: 2-s2.0-85028872119 07/01/2017 14 Citations

Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017 4 Citations

Recent advances in understanding multiple myeloma. (Hari P) Hematol Oncol Stem Cell Ther 2017 Dec;10(4):267-271 PMID: 28633036 SCOPUS ID: 2-s2.0-85021092247 06/21/2017 18 Citations

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. (Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM) Leukemia 2017 Nov;31(11):2443-2448 PMID: 28620163 SCOPUS ID: 2-s2.0-85031678437 06/18/2017 311 Citations

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. (Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG) Br J Haematol 2017 Aug;178(4):571-582 PMID: 28485007 PMCID: PMC5574012 SCOPUS ID: 2-s2.0-85019089968 05/10/2017 63 Citations

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 PMID: 28468799 PMCID: PMC5510790 SCOPUS ID: 2-s2.0-85023768076 05/05/2017 219 Citations

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. (Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A) Cancer 2017 Aug 15;123(16):3141-3149 PMID: 28472539 PMCID: PMC5544566 SCOPUS ID: 2-s2.0-85018446637 05/05/2017 81 Citations

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. (Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H) Leukemia 2017 Dec;31(12):2630-2641 PMID: 28439109 PMCID: PMC5729352 SCOPUS ID: 2-s2.0-85032905845 04/26/2017 23 Citations

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017 10 Citations

Marizomib for central nervous system-multiple myeloma. (Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P) Br J Haematol 2017 Apr;177(2):221-225 PMID: 28387460 SCOPUS ID: 2-s2.0-85017133877 04/08/2017 62 Citations

Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. (Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P) Biol Blood Marrow Transplant 2017 Jun;23(6):952-957 PMID: 28288949 SCOPUS ID: 2-s2.0-85017516033 03/16/2017 20 Citations

Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 SCOPUS ID: 2-s2.0-85015693044 03/13/2017 8 Citations

Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. (Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P) Biol Blood Marrow Transplant 2017 Jul;23(7):1193-1202 PMID: 28285082 SCOPUS ID: 2-s2.0-85019124812 03/13/2017 23 Citations

Disease burden of systemic light-chain amyloidosis: a systematic literature review. (Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P) Curr Med Res Opin 2017 Jun;33(6):1017-1031 PMID: 28277869 SCOPUS ID: 2-s2.0-85019629331 03/10/2017 28 Citations

Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856 PMID: 28161608 PMCID: PMC5410937 SCOPUS ID: 2-s2.0-85013473580 02/06/2017 38 Citations

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 Mar;17(3):165-172 PMID: 28159578 SCOPUS ID: 2-s2.0-85011032026 02/06/2017 20 Citations

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. (Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C) Leuk Lymphoma 2017 Aug;58(8):1872-1879 PMID: 28140719 SCOPUS ID: 2-s2.0-85011266750 02/01/2017 65 Citations

PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction. (Guzman-Villanueva D, Migrino RQ, Truran S, Karamanova N, Franco DA, Burciu C, Senapati S, Nedelkov D, Hari P, Weissig V) J Liposome Res 2018 Jun;28(2):97-105 PMID: 28103719 PMCID: PMC5591079 SCOPUS ID: 2-s2.0-85012101617 01/21/2017 7 Citations

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Dec;35(4):528-535 PMID: 28066928 SCOPUS ID: 2-s2.0-85009230369 01/10/2017 64 Citations

Instrumental variable with competing risk model. (Zheng C, Dai R, Hari PN, Zhang MJ) Stat Med 2017 Apr 15;36(8):1240-1255 PMID: 28064466 PMCID: PMC5479873 SCOPUS ID: 2-s2.0-85008471466 01/09/2017 14 Citations

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. (Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S) Clin Cancer Res 2017 Jul 01;23(13):3307-3315 PMID: 28053023 PMCID: PMC5496796 SCOPUS ID: 2-s2.0-85021106014 01/06/2017 226 Citations

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. (Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Feb;23(2):269-277 PMID: 27864161 PMCID: PMC5346183 SCOPUS ID: 2-s2.0-85008193410 11/20/2016 21 Citations

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. (Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P) Case Rep Hematol 2016;2016:2389038 PMID: 27843657 PMCID: PMC5097796 11/16/2016

HLA polymorphism and risk of multiple myeloma. (Beksac M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P) Leukemia 2016 Nov;30(11):2260-2264 PMID: 27461064 PMCID: PMC5134914 SCOPUS ID: 2-s2.0-84994355363 11/03/2016 21 Citations

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Jan;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 SCOPUS ID: 2-s2.0-85006371447 10/30/2016 17 Citations

Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. (Hari P, Raj RV, Olteanu H) N Engl J Med 2016 Oct 13;375(15):1501-1502 PMID: 27732828 SCOPUS ID: 2-s2.0-84991282075 10/13/2016 94 Citations

Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. (Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2016 Dec;16(12):672-678 PMID: 27660080 SCOPUS ID: 2-s2.0-84997605125 09/24/2016 7 Citations

Development of Novel Immunotherapies for Multiple Myeloma. (Al-Hujaily EM, Oldham RA, Hari P, Medin JA) Int J Mol Sci 2016 Sep 08;17(9) PMID: 27618026 PMCID: PMC5037783 SCOPUS ID: 2-s2.0-84987722672 09/13/2016 23 Citations

Recent advances in understanding multiple myeloma. (Dhakal B, Girnius S, Hari P) F1000Res 2016;5 PMID: 27610224 PMCID: PMC4995679 09/10/2016

Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 SCOPUS ID: 2-s2.0-84991038636 09/07/2016 13 Citations

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. (Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A) Biol Blood Marrow Transplant 2016 Oct;22(10):1893-1899 PMID: 27496215 PMCID: PMC5090978 SCOPUS ID: 2-s2.0-84992035513 08/09/2016 37 Citations

Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 Jan;52(1):147-150 PMID: 27479688 SCOPUS ID: 2-s2.0-84980370503 08/02/2016 7 Citations

Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? (Gallo S, Woolfrey AE, Burroughs LM, Storer BE, Flowers ME, Hari P, Pulsipher MA, Heimfeld S, Kiem HP, Sandmaier BM, Storb R) Bone Marrow Transplant 2016 Dec;51(12):1573-1578 PMID: 27479689 PMCID: PMC5143192 SCOPUS ID: 2-s2.0-84980350785 08/02/2016 14 Citations

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. (Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S) Bone Marrow Transplant 2017 Jan;52(1):59-65 PMID: 27427921 PMCID: PMC5215562 SCOPUS ID: 2-s2.0-84978696407 07/19/2016 20 Citations

Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. (Franco DA, Truran S, Weissig V, Guzman-Villanueva D, Karamanova N, Senapati S, Burciu C, Ramirez-Alvarado M, Blancas-Mejia LM, Lindsay S, Hari P, Migrino RQ) J Am Heart Assoc 2016 Jun 13;5(6) PMID: 27412900 PMCID: PMC4937272 SCOPUS ID: 2-s2.0-84991523248 07/15/2016 11 Citations

Resistant or Sensitive: Time Is of the Essence: Response to Malek et al. (Hari P) Biol Blood Marrow Transplant 2016 Oct;22(10):1908 PMID: 27387038 SCOPUS ID: 2-s2.0-84992160263 07/09/2016

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival Clinical Lymphoma, Myeloma and Leukemia 1 July 2016;16:379-386 07/01/2016

Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 PMID: 27345140 SCOPUS ID: 2-s2.0-84992043960 06/28/2016 8 Citations

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. (D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P) Br J Haematol 2017 Sep;178(5):816-819 PMID: 27292583 PMCID: PMC5154782 SCOPUS ID: 2-s2.0-84994285799 06/14/2016 3 Citations

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 Sep 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 SCOPUS ID: 2-s2.0-84989838395 06/09/2016 205 Citations

Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. (Krishnan A, Vij R, Keller J, Dhakal B, Hari P) Am Soc Clin Oncol Educ Book 2016;35:210-21 PMID: 27249701 SCOPUS ID: 2-s2.0-84994889855 06/02/2016 7 Citations

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 SCOPUS ID: 2-s2.0-84965053091 05/11/2016 22 Citations

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. (Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH) Biol Blood Marrow Transplant 2016 Aug;22(8):1391-1396 PMID: 27164062 PMCID: PMC5075527 SCOPUS ID: 2-s2.0-84981357619 05/11/2016 33 Citations

Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma. (Aljitawi OS, Hari P) Int J Hematol Oncol 2016 May;5(1):5-10 PMID: 30302199 PMCID: PMC6171969 05/01/2016

Mycobacterium mucogenicum bacteremia in immune-compromised patients, 2008-2013. (Abidi MZ, Ledeboer N, Banerjee A, Hari P) Diagn Microbiol Infect Dis 2016 Jun;85(2):182-5 PMID: 27117516 SCOPUS ID: 2-s2.0-84964211718 04/28/2016 7 Citations

Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. (Costa LJ, Hari PN, Kumar SK) Leuk Lymphoma 2016 Dec;57(12):2827-2832 PMID: 27104965 SCOPUS ID: 2-s2.0-84964492889 04/23/2016 51 Citations

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E) J Clin Oncol 2016 May 01;34(13):1544-57 PMID: 26976420 SCOPUS ID: 2-s2.0-84965050407 03/16/2016 360 Citations

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. (Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ) Case Rep Med 2016;2016:8503275 PMID: 26941799 PMCID: PMC4749780 SCOPUS ID: 2-s2.0-85011094757 03/05/2016 14 Citations

Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients. (Abidi MZ, Ledeboer N, Banerjee A, Hari P) Diagn Microbiol Infect Dis 2016 May;85(1):116-20 PMID: 26906191 SCOPUS ID: 2-s2.0-84959066272 02/26/2016 25 Citations

Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. (van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A) Haematologica 2016 May;101(5):634-43 PMID: 26869630 PMCID: PMC5004373 SCOPUS ID: 2-s2.0-84964780475 02/13/2016 38 Citations

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. (D'Souza A, Huang J, Hari P) Biol Blood Marrow Transplant 2016 Apr;22(4):768-770 PMID: 26743343 PMCID: PMC4801777 SCOPUS ID: 2-s2.0-84960472606 01/09/2016 6 Citations

Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016 20 Citations

Allogeneic stem cell transplantation for multiple myeloma: is there a future? (Dhakal B, Vesole DH, Hari PN) Bone Marrow Transplant 2016 Apr;51(4):492-500 PMID: 26726943 SCOPUS ID: 2-s2.0-84953338728 01/05/2016 54 Citations

Recent advances in understanding multiple myeloma. (Dhakal B, Girnius S, Hari P) F1000research 2016;5 SCOPUS ID: 2-s2.0-85010977523 01/01/2016 12 Citations

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. (Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V) Biol Blood Marrow Transplant 2016 Mar;22(3):432-40 PMID: 26493563 PMCID: PMC5030817 SCOPUS ID: 2-s2.0-84950996639 10/24/2015 130 Citations

Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. (Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A) Bone Marrow Transplant 2016 Feb;51(2):297-9 PMID: 26457907 PMCID: PMC4956087 SCOPUS ID: 2-s2.0-84956915976 10/13/2015 10 Citations

Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. (Zhu F, Heditke S, Kurtzberg J, Waters-Pick B, Hari P, Margolis DA, Keever-Taylor CA) Cytotherapy 2015 Dec;17(12):1813-9 PMID: 26454752 SCOPUS ID: 2-s2.0-84947594247 10/12/2015 16 Citations

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. (Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M) Bone Marrow Transplant 2016 Jan;51(1):58-66 PMID: 26437062 PMCID: PMC4703480 SCOPUS ID: 2-s2.0-84953367337 10/06/2015 37 Citations

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E) Biol Blood Marrow Transplant 2015 Dec;21(12):2039-2051 PMID: 26428082 PMCID: PMC4757494 SCOPUS ID: 2-s2.0-84947430469 10/03/2015 164 Citations

Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. (Epperla N, Fenske TS, Hari PN, Hamadani M) World J Transplant 2015 Sep 24;5(3):81-8 PMID: 26421260 PMCID: PMC4580930 10/01/2015

Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 PMID: 26422743 SCOPUS ID: 2-s2.0-84942932373 10/01/2015 31 Citations

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. (D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P) J Clin Oncol 2015 Nov 10;33(32):3741-9 PMID: 26371138 PMCID: PMC4737858 SCOPUS ID: 2-s2.0-84947461051 09/16/2015 186 Citations

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. (Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW) Biol Blood Marrow Transplant 2015 Nov;21(11):1883-7 PMID: 26371371 PMCID: PMC4604067 SCOPUS ID: 2-s2.0-84943418147 09/16/2015 39 Citations

Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. (Cornell RF, Hari P, Drobyski WR) Biol Blood Marrow Transplant 2015 Dec;21(12):2061-2068 PMID: 26327628 PMCID: PMC4639405 SCOPUS ID: 2-s2.0-84947416879 09/04/2015 91 Citations

A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. (Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K) Biol Blood Marrow Transplant 2015 Dec;21(12):2100-2105 PMID: 26327631 SCOPUS ID: 2-s2.0-84947484415 09/04/2015 30 Citations

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. (Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A) Bone Marrow Transplant 2015 Dec;50(12):1513-8 PMID: 26301967 PMCID: PMC4548821 SCOPUS ID: 2-s2.0-84949085500 08/25/2015 36 Citations

Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3 PMID: 26284951 PMCID: PMC4618044 SCOPUS ID: 2-s2.0-84944536944 08/19/2015 13 Citations

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099 PMID: 26253007 PMCID: PMC4639453 SCOPUS ID: 2-s2.0-84947494295 08/09/2015 54 Citations

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. (Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG) Cancer 2015 Oct 15;121(20):3709-16 PMID: 26207349 PMCID: PMC4592381 SCOPUS ID: 2-s2.0-84943581668 07/25/2015 35 Citations

Minimal residual disease testing after stem cell transplantation for multiple myeloma. (Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF) Bone Marrow Transplant 2016 Jan;51(1):2-12 PMID: 26191950 SCOPUS ID: 2-s2.0-84953346101 07/21/2015 22 Citations

CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. (Abidi MZ, D'Souza A, Kuppalli K, Ledeboer N, Hari P) Diagn Microbiol Infect Dis 2015 Sep;83(1):46-8 PMID: 25986028 SCOPUS ID: 2-s2.0-84938739008 05/20/2015 12 Citations

Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 SCOPUS ID: 2-s2.0-84934862607 04/29/2015 27 Citations

Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. (Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS) Bone Marrow Transplant 2015 Jul;50(7):947-53 PMID: 25867651 PMCID: PMC4490016 SCOPUS ID: 2-s2.0-84934795677 04/14/2015 39 Citations

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66 PMID: 25769794 SCOPUS ID: 2-s2.0-84930577739 03/15/2015 103 Citations

Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 SCOPUS ID: 2-s2.0-84926418285 01/27/2015 7 Citations

Autologous stem cell transplantation (Lazarus HM, Hamadani M, Hari PN) Devita Hellman and Rosenberg S Cancer Principles Practice of Oncology Tenth Edition 7 January 2015 SCOPUS ID: 2-s2.0-84976603200 01/07/2015 1 Citation

New cancers after autotransplantations for multiple myeloma. (Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN) Biol Blood Marrow Transplant 2015 Apr;21(4):738-45 PMID: 25555448 PMCID: PMC4359647 SCOPUS ID: 2-s2.0-84924259698 01/04/2015 42 Citations

Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. (Costa LJ, Huang JX, Hari PN) Biol Blood Marrow Transplant 2015 Apr;21(4):701-6 PMID: 25555447 PMCID: PMC4361014 SCOPUS ID: 2-s2.0-84924233017 01/04/2015 70 Citations

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. (Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN) Biol Blood Marrow Transplant 2015 Feb;21(2):335-41 PMID: 25445028 PMCID: PMC4297511 SCOPUS ID: 2-s2.0-84920873790 12/03/2014 66 Citations

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG) Lancet Oncol 2014 Dec;15(13):1503-1512 PMID: 25456369 SCOPUS ID: 2-s2.0-84925230724 12/03/2014 259 Citations

All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. (Karmali R, Dalovisio A, Borgia JA, Venugopal P, Kim BW, Grant-Szymanski K, Hari P, Lazarus H) Blood Rev 2015 Mar;29(2):71-80 PMID: 25433571 SCOPUS ID: 2-s2.0-84932602551 12/01/2014 21 Citations

Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51 PMID: 25387097 SCOPUS ID: 2-s2.0-84930383567 11/12/2014 12 Citations

Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 SCOPUS ID: 2-s2.0-84912142377 08/12/2014 26 Citations

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. (Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM) Haematologica 2014 Oct;99(10):1624-31 PMID: 25085357 PMCID: PMC4181260 SCOPUS ID: 2-s2.0-84907495257 08/03/2014 34 Citations

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. (Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN) Bone Marrow Transplant 2014 Nov;49(11):1360-5 PMID: 25068422 PMCID: PMC4221526 SCOPUS ID: 2-s2.0-84909982000 07/30/2014 95 Citations

Older patients with myeloma derive similar benefit from autologous transplantation. (Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P) Biol Blood Marrow Transplant 2014 Nov;20(11):1796-803 PMID: 25046833 PMCID: PMC4194262 SCOPUS ID: 2-s2.0-84908070200 07/22/2014 71 Citations

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK) Biol Blood Marrow Transplant 2014 Nov;20(11):1729-36 PMID: 25008330 PMCID: PMC4194275 SCOPUS ID: 2-s2.0-84908019168 07/11/2014 136 Citations

Allogeneic hematopoietic cell transplantation in multiple myeloma (Randhawa J, Singh V, Hari P) Cancer Consult Expertise for Clinical Practice June 20, 2014:381-387 SCOPUS ID: 2-s2.0-84946423263 06/20/2014

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). (Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP) Haematologica 2014 Sep;99(9):1479-85 PMID: 24859879 PMCID: PMC4562537 SCOPUS ID: 2-s2.0-84907321417 05/27/2014 117 Citations

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 SCOPUS ID: 2-s2.0-84900867182 05/03/2014 10 Citations

Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. (Kanate AS, Pasquini MC, Hari PN, Hamadani M) World J Stem Cells 2014 Apr 26;6(2):69-81 PMID: 24772235 PMCID: PMC3999783 04/29/2014

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. (Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2014 Aug;20(8):1183-9 PMID: 24769014 PMCID: PMC5036168 SCOPUS ID: 2-s2.0-84904068423 04/29/2014 90 Citations

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. (Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS) Br J Haematol 2014 Aug;166(3):401-9 PMID: 24761838 SCOPUS ID: 2-s2.0-84904063376 04/26/2014 41 Citations

Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. (Guddati AK, Kumar G, Ahmed S, Ali M, Kumar N, Hari P, Venu N) Int J Hematol 2014 Jun;99(6):758-65 PMID: 24715522 SCOPUS ID: 2-s2.0-84905392499 04/10/2014 36 Citations

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. (Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN) Biol Blood Marrow Transplant 2014 Mar;20(3):402-408.e1 PMID: 24342394 PMCID: PMC3961011 SCOPUS ID: 2-s2.0-84896811241 12/18/2013 99 Citations

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81 PMID: 24344210 PMCID: PMC3897255 SCOPUS ID: 2-s2.0-84897020212 12/18/2013 129 Citations

Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. (Freytes CO, Vesole DH, LeRademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN) Bone Marrow Transplant 2014 Mar;49(3):416-21 PMID: 24270389 PMCID: PMC3947725 SCOPUS ID: 2-s2.0-84904240000 11/26/2013 55 Citations

Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury. (Truran S, Weissig V, Ramirez-Alvarado M, Franco DA, Burciu C, Georges J, Murarka S, Okoth WA, Schwab S, Hari P, Migrino RQ) J Liposome Res 2014 Mar;24(1):69-73 PMID: 24236475 PMCID: PMC3925072 SCOPUS ID: 2-s2.0-84893272416 11/19/2013 14 Citations

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. (Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2014 Jan;20(1):89-97 PMID: 24161923 PMCID: PMC3886623 SCOPUS ID: 2-s2.0-84890911661 10/29/2013 127 Citations

Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. (Migrino RQ, Harmann L, Christenson R, Hari P) Heart Vessels 2014 Nov;29(6):793-800 PMID: 24141988 PMCID: PMC3992190 SCOPUS ID: 2-s2.0-84920946015 10/22/2013 15 Citations

Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. (Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN) Biol Blood Marrow Transplant 2013 Dec;19(12):1740-4 PMID: 24096096 PMCID: PMC3906436 SCOPUS ID: 2-s2.0-84887547882 10/08/2013 54 Citations

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. (Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC) Biol Blood Marrow Transplant 2013 Dec;19(12):1661-9 PMID: 24018393 PMCID: PMC3914636 SCOPUS ID: 2-s2.0-84887521007 09/11/2013 11 Citations

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. (Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN) Biol Blood Marrow Transplant 2013 Nov;19(11):1615-24 PMID: 23939198 PMCID: PMC3952066 SCOPUS ID: 2-s2.0-84885803622 08/14/2013 103 Citations

Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. (Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN) J Clin Oncol 2013 Sep 01;31(25):3100-9 PMID: 23897963 PMCID: PMC3753702 SCOPUS ID: 2-s2.0-84886463678 07/31/2013 199 Citations

Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. (Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN) Br J Haematol 2013 Sep;162(5):648-56 PMID: 23829536 PMCID: PMC3766698 SCOPUS ID: 2-s2.0-84881661687 07/09/2013 26 Citations

Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. (Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR) Biol Blood Marrow Transplant 2013 Sep;19(9):1368-73 PMID: 23806770 SCOPUS ID: 2-s2.0-84882809747 06/29/2013 34 Citations

Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. (Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ) Biol Blood Marrow Transplant 2013 Sep;19(9):1361-7 PMID: 23806773 SCOPUS ID: 2-s2.0-84882740395 06/29/2013 22 Citations

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. (Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM) Biol Blood Marrow Transplant 2013 Sep;19(9):1340-7 PMID: 23769990 PMCID: PMC3755028 SCOPUS ID: 2-s2.0-84882781560 06/19/2013 24 Citations

Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? (Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M) Bone Marrow Transplant 2013 Nov;48(12):1489-96 PMID: 23584438 SCOPUS ID: 2-s2.0-84889590282 04/16/2013 9 Citations

Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. (Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T, Martin PJ, Storb R, Maloney DG, Storer B, Flowers ME) Biol Blood Marrow Transplant 2013 Jun;19(6):949-57 PMID: 23523892 PMCID: PMC3846289 SCOPUS ID: 2-s2.0-84877880430 03/26/2013 85 Citations

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM) J Clin Oncol 2013 Apr 20;31(12):1530-8 PMID: 23478054 PMCID: PMC3625710 SCOPUS ID: 2-s2.0-84876329801 03/13/2013 193 Citations

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53 PMID: 23380340 PMCID: PMC3650915 SCOPUS ID: 2-s2.0-84876298990 02/06/2013 87 Citations

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31 PMID: 23333532 PMCID: PMC3640440 SCOPUS ID: 2-s2.0-84875481784 01/22/2013 77 Citations

Multiple myeloma: future directions in autologous transplantation and novel agents. (Hari PN, McCarthy PL) Biol Blood Marrow Transplant 2013 Jan;19(1 Suppl):S20-5 PMID: 23290439 SCOPUS ID: 2-s2.0-84871890286 01/11/2013 8 Citations

Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 SCOPUS ID: 2-s2.0-84876327529 01/10/2013 102 Citations

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9 PMID: 23200705 PMCID: PMC3553321 SCOPUS ID: 2-s2.0-84872527502 12/04/2012 47 Citations

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? (Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR) Blood 2012 Nov 15;120(20):4256-62 PMID: 23007405 PMCID: PMC3501720 SCOPUS ID: 2-s2.0-84869850112 09/26/2012 136 Citations

Protective role of clusterin in preserving endothelial function in AL amyloidosis. (Franco DA, Truran S, Burciu C, Gutterman DD, Maltagliati A, Weissig V, Hari P, Migrino RQ) Atherosclerosis 2012 Nov;225(1):220-3 PMID: 22981431 PMCID: PMC3478430 SCOPUS ID: 2-s2.0-84867867786 09/18/2012 18 Citations

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. (Gupta V, Hari P, Hoffman R) Blood 2012 Aug 16;120(7):1367-79 PMID: 22700718 PMCID: PMC5800543 SCOPUS ID: 2-s2.0-84865174824 06/16/2012 92 Citations

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. (Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM) J Clin Oncol 2012 Jul 10;30(20):2492-9 PMID: 22585697 PMCID: PMC4874149 SCOPUS ID: 2-s2.0-84864050584 05/16/2012 162 Citations

Lenalidomide after stem-cell transplantation for multiple myeloma. (McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C) N Engl J Med 2012 May 10;366(19):1770-81 PMID: 22571201 PMCID: PMC3744390 05/11/2012

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. (Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV) Blood 2012 May 10;119(19):4375-82 PMID: 22422823 SCOPUS ID: 2-s2.0-84860907057 03/17/2012 417 Citations

Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. (Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H) Am J Clin Pathol 2012 Mar;137(3):403-11 PMID: 22338052 SCOPUS ID: 2-s2.0-84859238276 02/18/2012 24 Citations

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. (Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN) Biol Blood Marrow Transplant 2012 Aug;18(8):1255-64 PMID: 22198543 PMCID: PMC3376237 SCOPUS ID: 2-s2.0-84864017956 12/27/2011 23 Citations

Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. (Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN) Biol Blood Marrow Transplant 2012 Jul;18(7):1036-1043.e1 PMID: 22155506 PMCID: PMC3894923 SCOPUS ID: 2-s2.0-84862130917 12/14/2011 17 Citations

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. (Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R) JAMA 2011 Nov 02;306(17):1874-83 PMID: 22045765 PMCID: PMC3217787 SCOPUS ID: 2-s2.0-80355129623 11/03/2011 282 Citations

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. (Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P) Leukemia 2012 May;26(5):1091-7 PMID: 22042147 PMCID: PMC3274611 SCOPUS ID: 2-s2.0-84860778432 11/02/2011 95 Citations

Percussion hemoglobinuria - a novel term for hand trauma-induced mechanical hemolysis: a case report. (Vasudev M, Bresnahan BA, Cohen EP, Hari PN, Hariharan S, Vasudev BS) J Med Case Rep 2011 Oct 07;5:508 PMID: 21982397 PMCID: PMC3213680 SCOPUS ID: 2-s2.0-80053480504 10/11/2011 9 Citations

Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. (Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P) Am J Physiol Heart Circ Physiol 2011 Dec;301(6):H2305-12 PMID: 21963839 PMCID: PMC3233808 SCOPUS ID: 2-s2.0-82855181178 10/04/2011 81 Citations

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN)) Lancet Oncol 2011 Dec;12(13):1195-203 PMID: 21962393 PMCID: PMC3611089 SCOPUS ID: 2-s2.0-82555179157 10/04/2011 267 Citations

Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. (Ringdén O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN) Bone Marrow Transplant 2012 Jun;47(6):831-7 PMID: 21946381 PMCID: PMC3369112 SCOPUS ID: 2-s2.0-84862177965 09/29/2011 29 Citations

Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ) Biol Blood Marrow Transplant 2012 May;18(5):690-7 PMID: 21875505 PMCID: PMC3762249 SCOPUS ID: 2-s2.0-84859878721 08/31/2011 63 Citations

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. (Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working Group) Leukemia 2012 Jan;26(1):149-57 PMID: 21799510 PMCID: PMC4109061 SCOPUS ID: 2-s2.0-84856719479 07/30/2011 667 Citations

Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. (Devata S, Hari P, Markelova N, Li R, Komorowski R, Shidham VB) Cytojournal 2011;8:11 PMID: 21760829 PMCID: PMC3132327 07/16/2011

Tocilizumab for the treatment of steroid refractory graft-versus-host disease. (Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1862-8 PMID: 21745454 PMCID: PMC3716013 SCOPUS ID: 2-s2.0-81255163590 07/13/2011 110 Citations

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN) Blood 2011 Aug 18;118(7):1979-88 PMID: 21690560 PMCID: PMC3158724 SCOPUS ID: 2-s2.0-80051878404 06/22/2011 67 Citations

Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. (Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1765-74 PMID: 21624486 PMCID: PMC3175301 SCOPUS ID: 2-s2.0-81255159031 06/01/2011 49 Citations

High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. (Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH) Bone Marrow Transplant 2012 Mar;47(3):399-403 PMID: 21478917 SCOPUS ID: 2-s2.0-84858075288 04/12/2011 17 Citations

Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ) Biol Blood Marrow Transplant 2011 Sep;17(9):1343-51 PMID: 21320619 PMCID: PMC3150599 SCOPUS ID: 2-s2.0-79960270124 02/16/2011 131 Citations

CD200 expression in plasma cell myeloma. (Olteanu H, Harrington AM, Hari P, Kroft SH) Br J Haematol 2011 May;153(3):408-11 PMID: 21275968 SCOPUS ID: 2-s2.0-79954419980 02/01/2011 39 Citations

Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. (Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN) Clin Lymphoma Myeloma Leuk 2010 Dec;10(6):458-63 PMID: 21156462 PMCID: PMC3370942 SCOPUS ID: 2-s2.0-79952904942 12/16/2010 27 Citations

Performing and processing FNA of anterior fat pad for amyloid. (Shidham VB, Hunt B, Jardeh SS, Barboi AC, Devata S, Hari P) J Vis Exp 2010 Oct 30(44) PMID: 21085098 PMCID: PMC3185617 SCOPUS ID: 2-s2.0-80355133732 11/19/2010 21 Citations

Access to hematopoietic stem cell transplantation: effect of race and sex. (Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM) Cancer 2010 Jul 15;116(14):3469-76 PMID: 20564154 PMCID: PMC3153958 SCOPUS ID: 2-s2.0-77954889709 06/22/2010 135 Citations

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. (Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV) Leukemia 2010 Jul;24(7):1350-6 PMID: 20508619 PMCID: PMC2957585 SCOPUS ID: 2-s2.0-77954660886 05/29/2010 77 Citations

Light chain amyloidosis circa 2010: six prognostic markers and one sobering reality. (Migrino RQ, Hari P) J Am Soc Echocardiogr 2010 Jun;23(6):653-5 PMID: 20497862 SCOPUS ID: 2-s2.0-77952618697 05/26/2010

Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. (Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P) Br J Haematol 2010 Aug;150(4):480-1 PMID: 20456357 SCOPUS ID: 2-s2.0-77955163811 05/12/2010 4 Citations

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. (Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN) Biol Blood Marrow Transplant 2010 Jan;16(1):35-45 PMID: 20053330 PMCID: PMC2929576 SCOPUS ID: 2-s2.0-72649090031 01/08/2010 84 Citations

A poetic diagnosis: An interesting case of peripheral neuropathy (Hirudayaraj P, Hari PN) Wisconsin Medical Journal December 2009;108(9):476-477 SCOPUS ID: 2-s2.0-77649278014 12/01/2009

Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. (Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzo JD, Mehta P) Biol Blood Marrow Transplant 2010 Mar;16(3):395-402 PMID: 19922808 PMCID: PMC2833344 SCOPUS ID: 2-s2.0-75749106529 11/20/2009 57 Citations

Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. (Migrino RQ, Mareedu RK, Eastwood D, Bowers M, Harmann L, Hari P) J Am Soc Echocardiogr 2009 Dec;22(12):1396-402 PMID: 19880277 PMCID: PMC2787973 SCOPUS ID: 2-s2.0-70450253173 11/03/2009 38 Citations

Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. (Harrington AM, Hari P, Kroft SH) Am J Clin Pathol 2009 Jul;132(1):60-6 PMID: 19864234 SCOPUS ID: 2-s2.0-67650471360 10/30/2009 27 Citations

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. (Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM) Biol Blood Marrow Transplant 2009 Nov;15(11):1455-64 PMID: 19822306 PMCID: PMC2913553 SCOPUS ID: 2-s2.0-70350587347 10/14/2009 53 Citations

Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry. (Conway EJ, Wen J, Feng Y, Mo A, Huang WT, Keever-Taylor CA, Hari P, Vesole DH, Chang CC) Arch Pathol Lab Med 2009 Oct;133(10):1594-9 PMID: 19792049 SCOPUS ID: 2-s2.0-70349647600 10/02/2009 12 Citations

Systemic and microvascular oxidative stress induced by light chain amyloidosis. (Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA) Int J Cardiol 2010 Nov 05;145(1):67-8 PMID: 19446898 PMCID: PMC2974792 SCOPUS ID: 2-s2.0-78049467563 05/19/2009 51 Citations

Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. (Migrino RQ, Christenson R, Szabo A, Bright M, Truran S, Hari P) BMC Med Phys 2009 May 05;9:5 PMID: 19416541 PMCID: PMC2686669 SCOPUS ID: 2-s2.0-67649739459 05/07/2009 35 Citations

Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. (van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN) Biol Blood Marrow Transplant 2009 May;15(5):554-63 PMID: 19361747 PMCID: PMC3120935 SCOPUS ID: 2-s2.0-63749130619 04/14/2009 29 Citations

Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. (Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D) Leukemia 2009 Aug;23(8):1528-34 PMID: 19322205 PMCID: PMC2726276 SCOPUS ID: 2-s2.0-68749084622 03/27/2009 88 Citations

Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. (Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P) Biol Blood Marrow Transplant 2009 Jan;15(1):109-17 PMID: 19135949 PMCID: PMC2929570 SCOPUS ID: 2-s2.0-58149197557 01/13/2009 97 Citations

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. (Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG) Blood 2009 Apr 02;113(14):3383-91 PMID: 19015394 PMCID: PMC2665904 SCOPUS ID: 2-s2.0-65149104407 11/19/2008 97 Citations

Case report: Delayed enhancement on cardiac MRI in a patient with multiple myeloma without amyloidosis. (Brahmbhatt T, Hari P, Cinquegrani M, Kumar N, Komorowski R, Migrino RQ) Br J Radiol 2008 Nov;81(971):e272-5 PMID: 18941041 SCOPUS ID: 2-s2.0-55249089219 10/23/2008 6 Citations

Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. (Kumar S, Pérez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P) Biol Blood Marrow Transplant 2008 Oct;14(10):1134-1140 PMID: 18804043 PMCID: PMC2634851 SCOPUS ID: 2-s2.0-51649085303 09/23/2008 27 Citations

Comparison of twin and autologous transplants for multiple myeloma. (Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee) Biol Blood Marrow Transplant 2008 Oct;14(10):1118-1124 PMID: 18804041 PMCID: PMC2584240 SCOPUS ID: 2-s2.0-51649085791 09/23/2008 28 Citations

Nonmyeloablative conditioning for relapsed follicular lymphoma. (van Besien K, Hari P) Blood 2008 Sep 15;112(6):2585-6; author reply 2586-7 PMID: 18779408 SCOPUS ID: 2-s2.0-55249111840 09/10/2008 1 Citation

Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. (Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W) Bone Marrow Transplant 2009 Jan;43(2):169-77 PMID: 18762759 SCOPUS ID: 2-s2.0-59549095162 09/03/2008 34 Citations

Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. (Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P) Cardiovasc Ultrasound 2008 Aug 07;6:40 PMID: 18687125 PMCID: PMC2525629 SCOPUS ID: 2-s2.0-50249118246 08/09/2008 21 Citations

Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P) Biol Blood Marrow Transplant 2008 Aug;14(8):904-12 PMID: 18640574 PMCID: PMC3353768 SCOPUS ID: 2-s2.0-47249135075 07/22/2008 51 Citations

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. (Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K) Biol Blood Marrow Transplant 2008 Feb;14(2):236-45 PMID: 18215784 PMCID: PMC2531158 SCOPUS ID: 2-s2.0-38149063716 01/25/2008 151 Citations

Response to Dr. Dai et al. [4] (Surapaneni SN, Hari P, Saeian K) American Journal of Gastroenterology October 2007;102(10):2351-2352 SCOPUS ID: 2-s2.0-34848889240 10/01/2007

Multiple myeloma: charging toward a bright future. (Katzel JA, Hari P, Vesole DH) CA Cancer J Clin 2007;57(5):301-18 PMID: 17855486 SCOPUS ID: 2-s2.0-35448934091 09/15/2007 95 Citations

Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. (Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K) Am J Gastroenterol 2007 Feb;102(2):449-51 PMID: 17100972 SCOPUS ID: 2-s2.0-33846547897 11/15/2006 14 Citations

New questions about transplantation in multiple myeloma. (Hari P, Pasquini MC, Vesole DH) Oncology (Williston Park) 2006 Sep;20(10):1230-42; discussion 1242, 1244, 1249-50 PMID: 17024872 SCOPUS ID: 2-s2.0-34250634391 10/10/2006 5 Citations

Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. (Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA) Biol Blood Marrow Transplant 2006 Aug;12(8):845-54 PMID: 16864055 SCOPUS ID: 2-s2.0-33746261518 07/26/2006 61 Citations

Reversible posterior leukoencephalopathy syndrome and bevacizumab. (Ozcan C, Wong SJ, Hari P) N Engl J Med 2006 Mar 02;354(9):980-2; discussion 980-2 PMID: 16514715 03/04/2006

Reversible posterior leukoencephalopathy syndrome and bevacizumab [21] (Ozcan C, Wong SJ, Hari P) New England Journal of Medicine 2 March 2006;354(9):981-982 SCOPUS ID: 2-s2.0-33644599473 03/02/2006 73 Citations

Cure of multiple myeloma -- more hype, less reality. (Hari P, Pasquini MC, Vesole DH) Bone Marrow Transplant 2006 Jan;37(1):1-18 PMID: 16258534 SCOPUS ID: 2-s2.0-31344453763 11/01/2005 26 Citations

NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. (Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR) Blood 2006 Jan 15;107(2):827-34 PMID: 16174760 PMCID: PMC1895627 SCOPUS ID: 2-s2.0-30444458109 09/22/2005 110 Citations

Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity? (Hari P, Logan B, Drobyski WR) Biol Blood Marrow Transplant 2004 Nov;10(11):743-7 PMID: 15505605 SCOPUS ID: 2-s2.0-6444236370 10/27/2004 9 Citations

A pain in the back. (Rees JH) N Engl J Med 2001 Feb 08;344(6):456; author reply 456-7 PMID: 11221604 SCOPUS ID: 2-s2.0-0035825732 02/28/2001

Mother-to-child HCV transmission. (Hari P, Prasad CG, Lankipalli R) Lancet 2001 Jan 13;357(9250):142; author reply 143 PMID: 11197421 02/24/2001

High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. (Hari P, Prasad Chemiti GK, Lankipalli RS) N Engl J Med 2000 Dec 28;343(26):1968-9 PMID: 11186673 SCOPUS ID: 2-s2.0-0034727812 02/24/2001 6 Citations

Mother-to-child HCV transmission. (Semprini AE, Savasi V, Hollander L, Tanzi E) Lancet 2001 Jan 13;357(9250):141; author reply 143 PMID: 11197418 SCOPUS ID: 2-s2.0-0035852493 02/24/2001 7 Citations

Last update: 11/13/2024

© 2026 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Parameswaran Hari MD

Adjunct Professor

Publications (391)